Teva Pharmaceuticals USA, Inc.

Get AJOVY delivered to your door with fast shipping nationwide.

Never wait in line at the pharmacy again.

Patients pay as little as $0 out-of-pocket for AJOVY.
Teva Pharmaceuticals USA, Inc. will pay the remaining co-payment or cost-sharing obligation per fill.

Once your prescription is transferred, it is shipped in 1-2 days.

Manufacturer Promotional Price



available on all qualifying 90-day Ajovy® orders

Select Medication

* Valid prescription required. Patient must meet all eligibility
requirements to apply discount coupon.

Why migraine patients love Truepill

Easy Rx Transfer

A licensed pharmacist will review your information online and transfer your medication automatically.

Fast Shipping

No need to wait in line at a pharmacy. Your FDA-approved medications are delivered straight to your door.

Ongoing Support

Message a pharmacist anytime online for support with your treatment, and get refills delivered automatically.

What people are saying about AJOVY

Talk to a member
of our team

If you have any questions please contact our care team at (650) 353-5495 or support@truepill.com

We accept your insurance

We accept a wide range of insurance providers. If you have any coverage questions give us a call at (650) 399-9905 or go through the order process and enter your insurance. We will contact you to let you know your copay pricing.


We offer two categories of migraine medications - medications for immediate relief and preventative medications. Your doctor will design a treatment plan tailored to your situation, to reduce the number of migraines you experience each month. Learn more about migraine medications
The initial doctor consult is $20 with or without insurance. For medications, we accept all major insurance plans. Your insurance copays are dependant on your insurance provider. We will run your insurance claim and notify you of your copay before shipping your medications.
Yes, you can purchase the medications your doctor prescribes as part of your treatment plan at our cash price.
We accept all major insurance providers and can run your insurance to tell you what your copay will be. Your copays will always be the exact same as what you pay at your current pharmacy.

We will ask you during your order completion process if you want to use insurance or cash. If you select insurance you can provide your insurance details and we will notify you of your copay pricing. We will also always compare your copay pricing with the cash price of the drug and give you full control to choose how you want to pay for your medication.
Truepill is a licensed U.S. pharmacy and ships to all 50 states and Washington DC. We currently do not ship to Puerto Rico and other U.S. territories.

AJOVY Details

11 DESCRIPTION Fremanezumab-vfrm is a fully humanized IgG2Δa/kappa monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Fremanezumab-vfrm is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The antibody consists of 1324 amino acids and has a molecular weight of approximately 148 kDa. AJOVY (fremanezumab-vfrm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection, supplied in a single-dose 225 mg/1.5 mL prefilled syringe. Each prefilled syringe delivers 1.5 mL of solution containing 225 mg fremanezumab-vfrm, disodium ethylenediaminetetraacetic acid dihydrate (EDTA) (0.204 mg), L-histidine (0.815 mg), L-histidine hydrochloride monohydrate (3.93 mg), polysorbate-80 (0.3 mg), sucrose (99 mg), and Water for Injection, and has a pH of 5.5.
5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: If hypersensitivity occurs, consider discontinuing AJOVY and institute appropriate therapy. (5.1) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria, were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY, and institute appropriate therapy.
6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] The most common adverse reactions (≥5% and greater than placebo) were injection site reactions. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in clinical practice. The safety of AJOVY was evaluated in 2512 patients with migraine who received at least 1 dose of AJOVY, representing 1279 patient-years of exposure. Of these, 1730 patients were exposed to AJOVY 225 mg monthly or AJOVY 675 mg quarterly for at least 6 months, 775 patients for at least 12 months, and 138 patients for at least 15 months. In placebo-controlled clinical trials (Studies 1 and 2), 662 patients received AJOVY 225 mg monthly for 12 weeks (with or without a loading dose of 675 mg), and 663 patients received AJOVY 675 mg quarterly for 12 weeks [see Clinical Studies (14)]. In the controlled trials, 87% of patients were female, 80% were White, and the mean age was 41 years. The most common adverse reactions in the clinical trials for the preventive treatment of migraine (incidence at least 5% and greater than placebo) were injection site reactions. The adverse reactions that most commonly led to discontinuations were injection site reactions (1%). Table 1 summarizes adverse reactions reported in the 3-month placebo-controlled studies (Study 1 and Study 2), and the 1-month follow-up period after those studies. Table 1: Adverse Reactions Occurring with an Incidence of At Least 2% for Either Dosing Regimen of AJOVY and At Least 2% Greater Than Placebo in Studies 1 and 2 Adverse Reaction AJOVY 225 mg Monthly (n=290) % AJOVY 675 mg Quarterly (n=667) % Placebo Monthly (n=668) % Injection site reactionsa 43 45 38 a Injection site reactions include multiple related adverse event terms, such as injection site pain, induration, and erythema. 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to fremanezumab-vfrm in the studies described below with the incidence of antibodies in other studies to other products may be misleading. Clinical immunogenicity of AJOVY was monitored by analyzing anti-drug antibodies (ADA) and neutralizing antibodies in drug-treated patients. The data reflect the percentage of patients whose test results were positive for antibodies to AJOVY in specific assays. In 3-month placebo-controlled studies, treatment-emergent ADA responses were observed in 6 out of 1701 (0.4%) AJOVY-treated patients. One of the 6 patients developed anti-AJOVY neutralizing antibodies at Day 84. In the ongoing long-term open-label study, ADA were detected in 1.6% of patients (30 out of 1888). Out of 30 ADA-positive patients, 17 had a neutralizing activity in their post-dose samples. Although these data do not demonstrate an impact of anti-fremanezumab-vfrm antibody development on the efficacy or safety of AJOVY in these patients, the available data are too limited to make definitive conclusions.